Home > Inhibitors & Agonists > Others

Others

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC3967 P505-15 Acetate Selective spleen tyrosine kinase (SYK) inhibitor, suppressing leukocyte immune function and inflammation, and leading to a reduction in arthritis score and attenuated histological damage
DCC3968 p53 Modulator 10d Novel modulator of p53 activity, arresting at G2/M phase inducing delay of cell cycle progression
DCC3969 P53 Reactivator C85 Novel reactivator of mutant p53, fuctioning as a zinc metallochaperone (ZMC) with diminished copper binding that functions as a chemotherapy and radiation sensitizer
DCC3970 P5-peptide Novel inhibitor of atherogenesis and diabetes, significantly and specifically inhibiting αD-CEP binding
DCC3971 P7 Peptide Novel bFGF antagonist peptide, inhibiting breast cancer cell growth
DCC3972 P7c3a20 Neuroprotective agent, protecting ventral horn spinal cord motor neurons from cell death
DCC3973 P97-in-17 Novel potent inhibitor of the AAA+ ATPase p97
DCC3974 P97-in-23 Novel potent inhibitor of the AAA+ ATPase p97
DCC3975 Pa Autoinducer Pseudomonas aeruginosa autoinducer
DCC3976 Pa-082 Novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ), recruiting PPARγ-coactivator-1α, preventing triglyceride accumulation, and potentiating insulin signaling in vitro
DCC3977 Pa1 Dihydrochloride Photoswitchable epithelial sodium channel (ENaC) blocker
DCC3978 Paba/no Novel glutathione-S-transferase-p-activated nitric oxide donor, inhibiting proliferation and inducing apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells
DCC3979 Pad3-in-14b Novel potent and selective inhibitor of protein arginine deiminase 3 (PAD3), having 15600 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4.
DCC3980 pal-1045 Partial DAT/5-HT transporter substrate
DCC3981 pal-1046 Full DAT/5-HT transporter substrate
DCC3982 Pal-12 Novel selective LYPLAL1 activator, increasing LYPLAL1’s catalytic activity likely by enhancing the efficiency of the catalytic triad charge-relay system, confering beneficial effects in a mouse model of diet-induced obesity
DCC3983 pal-287 Full DAT/5-HT transporter substrate; Non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine; Full agonist at 5-HT2B and partial agonist at 5-HT2C
DCC3984 Pal-545 Hydrochloride Potent dual dopamine-serotonin (DA/5-HT) releaser
DCC3985 Palbociclib Dihydrochloride Featured Selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
DCC3986 Palmostatin M Novel Ras-Signaling Modulator, targeting acyl protein thioesterase 1 (APT1) and 2 (APT2) in cells
DCC3987 Palonosetron Potent serotonin-3 (5-HT3) receptor antagonist
DCC3988 Pam2cys Novel TLR2 agonist as potential adjuvant for cancer vaccines
DCC3989 Pancratistatin Inhibitor of the Cell_cycle>cell cycle from G0/G1 to S phase with powerful antiparasite activity
DCC3990 Panduratin A Biological Active Reagents
DCC3991 panomifene Tamoxifen analogue; antiestrogenic
DCC3992 Pan-raf/rtk Inhibitor I-16 Novel potent pan-Raf and receptor tyrosine kinase inhibitor, potently inhibits all subtypes of Rafs with IC50 values of 3.49 (BRafV600E), 8.86 (ARaf), 5.78 (BRafWT), and 1.65 nM (CRaf), respectively
DCC3993 Pao-pdt Potent and highly selective small molecule inhibitor of thioredoxin reductase (TrxR)
DCC3994 Pape-1 Pathway Preferential Estrogen, activating the extranuclear signaling pathway without activity on the nuclear signaling pathway
DCC3996 Para-aminoblebbistatin Blebbistatin derivative, increasing water solubility, decreases the inherent fluorescence, stabilizing the molecule to circumvent its degradation by prolonged blue light exposure, and decreasing its phototoxicity while retaining the in vitro and in vivo a
DCC3997 Para-cid-5951923 Isomer of CID-5951923

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>